Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are underway and says he's extremely thrilled with the results to date from its first-in-human study. Paterson's expecting the company will end the year achieving all milestones set for 2020.